CD8A and neoplasm: To assess whether the increase in tumor-infiltrating CD8+ TPEX extended to other chemotherapy classes apart from anti-metabolites, we characterized CD8+ TPEX after two doses (+6) of cisplatin (CP) or cyclophosphamide (CTX) in both AB1-HA and CT26 (online supplemental figure S2J).